Regarding vaccines based on specific PC TAAs target of autoantibodies, although PC vaccines should be particularly promising treatment options because PC develops slower than most cancers (209), only the analyses of NY-ESO-1 or Survivin have been also reported as cancer vaccines based on TAAs target of autoantibodies, with no other studies related to the TAAs discussed here as more specific of PC. This evidence concerns the gene BIRC5 and pachyonychia congenita.